Biofil Chemicals & Pharmaceuticals Ltd Stock Price Today (NSE: BIOFILCHEM)
Fundamental Score
Biofil Chemicals & Pharmaceuticals Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Biofil Chemicals & Pharmaceuticals Ltd share price today is ₹34.37, down 1.29% on NSE/BSE as of 23 June 2026. Biofil Chemicals & Pharmaceuticals Ltd (BIOFILCHEM) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹60.21 (Cr). The 52-week high for BIOFILCHEM share price is ₹48.50 and the 52-week low is ₹25.60. At a P/E ratio of 21.13x, BIOFILCHEM is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 3.03% and a debt-to-equity ratio of 0.00.
Biofil Chemicals & Pharmaceuticals Ltd Share Price Chart — NSE/BSE Historical Performance
Biofil Chemicals & Pharmaceuticals Ltd share price chart: 5.32% return over the past month. 52-week high ₹48.50, 52-week low ₹25.60.
Biofil Chemicals & Pharmaceuticals Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹34.40 | ₹35.00 | ₹34.25 | ₹34.37 | 12.18K (Cr) | |
| ₹35.09 | ₹36.80 | ₹34.11 | ₹34.82 | 1.22L (Cr) | |
| ₹36.85 | ₹36.85 | ₹34.80 | ₹35.09 | 32.24K (Cr) | |
| ₹37.60 | ₹39.99 | ₹34.35 | ₹35.62 | 2.84L (Cr) | |
| ₹31.22 | ₹37.82 | ₹31.22 | ₹36.92 | 7.42L (Cr) | |
| ₹31.77 | ₹32.14 | ₹31.21 | ₹31.52 | 7.87K (Cr) | |
| ₹31.99 | ₹32.25 | ₹31.24 | ₹31.77 | 3.73K (Cr) | |
| ₹31.55 | ₹32.49 | ₹31.10 | ₹31.55 | 4.53K (Cr) | |
| ₹31.50 | ₹32.00 | ₹31.26 | ₹31.56 | 5.04K (Cr) | |
| ₹31.50 | ₹32.99 | ₹31.11 | ₹31.88 | 13.34K (Cr) |
Biofil Chemicals & Pharmaceuticals Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹35.09 | ₹36.80 | ₹34.11 | ₹34.37 | -2.05% | |
| ₹33.10 | ₹39.99 | ₹31.10 | ₹35.09 | +6.01% | |
| ₹26.69 | ₹36.30 | ₹26.51 | ₹34.05 | +27.58% | |
| ₹30.51 | ₹32.25 | ₹25.60 | ₹25.79 | -15.47% | |
| ₹39.00 | ₹46.34 | ₹31.25 | ₹32.04 | -17.85% | |
| ₹33.92 | ₹38.40 | ₹28.50 | ₹29.26 | -13.74% | |
| ₹37.20 | ₹38.25 | ₹32.52 | ₹33.57 | -9.76% | |
| ₹39.50 | ₹40.74 | ₹35.50 | ₹37.23 | -5.75% | |
| ₹40.72 | ₹43.47 | ₹38.00 | ₹39.74 | -2.41% | |
| ₹43.99 | ₹45.00 | ₹40.60 | ₹41.64 | -5.34% | |
| ₹44.20 | ₹45.30 | ₹41.10 | ₹44.50 | +0.68% | |
| ₹47.17 | ₹47.95 | ₹43.04 | ₹44.90 | -4.81% |
AI Research Briefing
Powered by Gemini · 2026-04-17
Micro-cap pharma play with weak fundamentals, riding sector tailwinds but facing significant execution risks.
WHAT'S HAPPENING NOW (last 2-4 weeks)
No major catalysts found after live search. Biofil Chemicals declared non-applicability under SEBI's Large Corporate framework as of March 31, 2026, due to low outstanding borrowings of They also published newspaper notices regarding SEBI's special window for physical share dematerialization.
CORE STORY (THE REAL GAME)
Biofil is a micro-cap pharma company, likely attempting to ride the broader 'Make in India' and pharma innovation wave. The real game is whether they can scale beyond basic drugs and chemicals and tap into higher-margin opportunities.
- Positive sector sentiment from India Pharma 2026
- Near-zero debt offers financial flexibility
- Significant order wins
- Successful expansion into higher-margin products
- Improved profitability and cash flow
- Micro/SME cap - liquidity risk
- Negative 5Y profit and EPS CAGR
- Low promoter holding with slight decrease
FII shareholding decreased by 100% in the past year.
India Pharma 2026 highlights policy push, innovation driving sectoral growth.
Free Cash Flow 5Y is ₹0.95 Cr, indicating poor cash conversion.
If Biofil can execute on expansion plans and improve profitability, it could be a compelling turnaround story. However, significant execution risk remains.
Primary Thesis Risk
Inability to scale operations and improve profitability will lead to capital erosion.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Biofil Chemicals & Pharmaceuticals Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Biofil Chemicals & Pharmaceuticals Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of BIOFILCHEM across key market metrics for learning purposes.
Positive Indicators
6 factors identified
Attractive Valuation (P/E: 21.13 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (300.00%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (461.83%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (112.67x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
8 factors identified
Below-Average Return on Equity (3.03%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (4.12%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Margin Pressure Concerns (3.56%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges.
Limited Growth History (2.38% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Weak Earnings Growth (-14.28% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (-14.28% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Limited Institutional Interest (FII+DII: 0.08%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Biofil Chemicals & Pharmaceuticals Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Biofil Chemicals & Pharmaceuticals Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Biofil Chemicals & Pharmaceuticals LtdBiofil Chemical...Selected✓ BIOFILCHEM • 524396 | 45.4/100 | ₹34.37₹34 | ₹60.21₹60.21 | 21.13Average 21.1 Average | 3.03%Poor 3.03% Poor | 4.12%Poor 4.12% Poor | 0.00Excellent 0.0 Excellent | -14.28%Poor -14.28% Poor | 2.38%Average 2.38% Average | 0.00% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1844.30₹1844 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6797.50₹6798 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4537.80₹4538 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1418.20₹1418 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1319.00₹1319 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2276.40₹2276 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹956.95₹957 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2420.40₹2420 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1435.90₹1436 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5451.50₹5452 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Biofil Chemicals & Pharmaceuticals Ltd PE Ratio History
Historical price-to-earnings ratio for BIOFILCHEM — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2024 | ₹0.44 | ₹57.45 | 130.6x |
| FY 2023 | ₹0.34 | ₹54.15 | 159.3x |
| FY 2022 | ₹0.44 | ₹55.20 | 125.5x |
| FY 2021 | ₹0.77 | ₹62.35 | 81x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Biofil Chemicals & Pharmaceuticals Ltd Quarterly Performance
Latest quarterly metrics for BIOFILCHEM — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
461.83%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
300.00%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
2.38%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
-14.28%
Compounded annual net profit growth over 5 years
Biofil Chemicals & Pharmaceuticals Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for BIOFILCHEM — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Biofil Chemicals & Pharmaceuticals Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Biofil Chemicals & Pharmaceuticals Ltd (BIOFILCHEM) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Biofil Chemicals & Pharmaceuticals Ltd
About BIOFILCHEM (Biofil Chemicals & Pharmaceuticals Ltd)
Biofil Chemicals & Pharmaceuticals Ltd is a dynamic and innovative pharmaceutical company dedicated to advancing healthcare solutions. The company operates with a commitment to qua...lity, safety, and efficacy in the development, manufacturing, and distribution of a diverse range of pharmaceutical products. Biofilchem's core focus lies in addressing unmet medical needs and improving patient outcomes through cutting-edge research and development. Their state-of-the-art manufacturing facilities adhere to stringent international quality standards, ensuring that every product meets the highest level of excellence. They are driven by a team of experienced professionals and scientists, dedicated to discovering, developing, and delivering innovative therapies that make a meaningful difference in people's lives. Biofilchem is committed to ethical business practices and environmental sustainability, reflecting their responsibility towards society. Biofilchem stands as a multifaceted pharmaceutical entity, producing both active pharmaceutical ingredients (APIs) and finished dosage forms. Their expertise extends to the intricate synthesis of essential drug components and the formulation of safe and effective medications. They have built a reputation for providing high-quality, affordable medicines across various therapeutic areas, including but not limited to anti-infectives, cardiovascular, and central nervous system treatments. Beyond in-house production, Biofilchem actively collaborates with other pharmaceutical companies, offering contract manufacturing services that leverage their advanced facilities and regulatory expertise. This collaborative approach allows them to contribute to the broader healthcare ecosystem, ensuring a reliable supply of quality medications to meet growing demands. At the heart of Biofilchem's philosophy is a patient-centric approach, driving them to constantly innovate and improve their product offerings. They strive to understand the evolving needs of healthcare providers and patients, focusing on developing user-friendly formulations and convenient dosage forms. The company invests significantly in research and development, exploring novel drug delivery systems and developing generic versions of essential medicines. This commitment to innovation ensures access to affordable healthcare for a wider population. Biofilchem's dedication to quality, innovation, and ethical practices positions them as a trusted partner in the pharmaceutical industry, contributing to a healthier future for all.
Company Details
Key Leadership
BIOFILCHEM Share Price: Frequently Asked Questions
What is the current share price of Biofil Chemicals & Pharmaceuticals Ltd?
Biofil Chemicals & Pharmaceuticals Ltd (BIOFILCHEM) trades at ₹34.37 on NSE and BSE. Market cap ₹60.21 (Cr). Educational data only.
What is the P/E ratio of Biofil Chemicals & Pharmaceuticals Ltd?
Biofil Chemicals & Pharmaceuticals Ltd has a P/E of 21.13x vs industry average 31.77x.
What is the Bull Run score for Biofil Chemicals & Pharmaceuticals Ltd?
Biofil Chemicals & Pharmaceuticals Ltd has a Bull Run score of 45.4/100 based on 25+ financial parameters.
Does Biofil Chemicals & Pharmaceuticals Ltd pay dividends?
Biofil Chemicals & Pharmaceuticals Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Biofil Chemicals & Pharmaceuticals Ltd?
Biofil Chemicals & Pharmaceuticals Ltd has ROE of 3.03%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Biofil Chemicals & Pharmaceuticals Ltd?
Biofil Chemicals & Pharmaceuticals Ltd has debt-to-equity of 0.00.
Is Biofil Chemicals & Pharmaceuticals Ltd a good investment?
Bull Run gives Biofil Chemicals & Pharmaceuticals Ltd a score of 45.4/100. This is not investment advice — consult a SEBI-registered advisor.